SIC
DFTX

SJS Investment Consulting’s Definium Therapeutics DFTX Stock Holding History

SJS Investment Consulting’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12
Closed -$69 – 1667
2024
Q3 		$69 Hold
12
– – ﹤0.01% 1595
2024
Q2 		$87 Hold
12
– – ﹤0.01% 1587
2024
Q1 		$113 Sell
12
-2
-14% -$11 ﹤0.01% 1561
2023
Q4 		$52 Hold
14
– – ﹤0.01% 1589
2023
Q3 		$44 Hold
14
– – ﹤0.01% 1598
2023
Q2 		$50 Hold
14
– – ﹤0.01% 1561
2023
Q1 		$45 Hold
14
– – ﹤0.01% 1527
2022
Q4 		$31 Buy
14
+12
+600% +$33 ﹤0.01% 1564
2022
Q3 		$0 Buy
+2
New +$19 ﹤0.01% 1342
2022
Q1 		$0 Sell
2
-267
-99% -$4.63K ﹤0.01% 1105
2021
Q4 		$6K Buy
+269
New +$8.59K ﹤0.01% 410

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SJS Investment Consulting's DFTX Position: Q4 2024 in Review

SJS Investment Consulting sold out of Definium Therapeutics (DFTX) in Q4 2024, closing a stake of 12 shares — an estimated $69 sold.

SJS Investment Consulting first reported a position in DFTX in Q4 2021 and held it in 11 quarters. The position peaked at $6K in Q4 2021. 172 funds tracked by Wall St. Rank hold DFTX as of Q4 2024.

  • SJS Investment Consulting reported no remaining Definium Therapeutics position as of Q4 2024 after selling out during the quarter.
  • SJS Investment Consulting sold 12 Definium Therapeutics shares in Q4 2024, an estimated $69.
  • SJS Investment Consulting first reported a position in Definium Therapeutics in Q4 2021 and held it in 11 quarters.
  • SJS Investment Consulting's Definium Therapeutics position peaked at $6K in Q4 2021.
  • 172 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2024.

Based on SJS Investment Consulting's 13F filing for Q4 2024, filed 21 Jan 2025.